神经精神药理学治疗药物监测共识指南:2017版  

Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:update 2017

作　　者：C.Hiemke N.Bergemann H.W.Clement A.Conca J.Deckert K.Domschke G.Eckermann K.Egberts M.Gerlach C.Greiner G.Gründer E.Haen U.Havemann-Reinecke G.Hefner R.Helmer G.Janssen E.Jaquenoud G.Laux T.Messer R.M ssner M.JMüller M.Paulzen B.Pfuhlmann P.Riederer A.Saria B.Schoppek G.Schoretsanitis M.Schwarz M.Silva Gracia B.Stegmann W.Steimer J.C.Stingl M.Uhr S.Ulrich S.Unterecker R.Waschgler G.Zernig G.Zurek P.Baumann 李文标(译) 果伟(译) 贺静(译) 鲍爽(译) 路钊(译) 牛梦溪(译) 阮灿军(译) 臧彦楠(译) 王勇(译)[35] 张玲(译) 刘辰庚(译) 李洁(译)[35] 汤宜朗(译) 王传跃(译) 王刚(译) LI Wen-biao;GUO Wei;HE Jing

机构地区：[1]Department of Psychiatry and Psychotherapy,University Medical Center of Mainz,Mainz,Germany [2]Institute of Clinical Chemistry and Laboratory Medicine,University Medical Center of Mainz,Mainz,Germany [3]Kitzberg Hospitals,Center for Psychosomatic Medicine and Psychotherapy,Bad Mergentheim,Germany [4]Department of Child and Adolescent Psychiatry,University of Freiburg,Freiburg,Germany [5]Servizio Psichiatrico del Comprensorio Sanitario di Bolzano,Bolzano,Italy [6]Department of Psychiatry,Psychotherapy and Psychosomatics,University Hospital of Würzburg,Germany [7]Department of Psychiatry and Psychotherapy,Medical Center-University of Freiburg,Faculty of Medicine,University of Freiburg,Freiburg,Germany [8]Psychiatric Hospital,Kaufbeuren,Germany [9]Department of Child and Adolescent Psychiatry,Psychosomatics and Psychotherapy,Center of Mental Health,University Hospital of Würzburg,Germany [10]Federal Institute for Drugs and Medical Devices(BfArM),Bonn,Germany [11]Department of Psychiatry,Psychotherapy and Psychosomatics,RWTH Aachen University,Aachen,and JARA–Translational Brain Medicine,Aachen,Germany [12]Clinical Pharmacology,Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology,University of Regensburg,Regensburg,Germany [13]Department of Psychiatry and Psychosomatics,University of G ttingen,G ttingen,Germany [14]Psychiatric Hospital,Vitos Klinik,Eichberg,Eltville,Germany [15]Center of Epilepsy,Bielefeld,Germany [16]Medical Laboratory Stein,Limbach Group,M nchengladbach,Germany [17]Psychiatric Hospital,K nigsfelden,Brugg,Aargau,Switzerland [18]Institute of Psychological Medicine,Haag in Oberbayern,Germany [19]Danuviuskliniken,Psychiatric Hospital,Pfaffenhofen,Germany [20]Department of Psychiatry and Psychotherapy,University of Tübingen,Tübingen,Germany [21]Psychiatric Hospitals Oberberggruppe,Berlin,Germany [22]Psychiatric Hospital Weisser Hirsch,Dresden,Germany [23]Experimental Psychiatry Unit,Department of Psychiatry1,Medical University of Innsbruck,Innsbruck,Austria [2

出　　处：《实用药物与临床》2022年第2期97-118,共22页Practical Pharmacy and Clinical Remedies

基　　金：首都临床特色应用研究与成果推广项目(Z171100001017075);北京市属医院科研培训计划项目(PZ2020031)。

摘　　要：2.2剂量相关参考浓度范围对于TDM结果的解释,除了治疗参考浓度范围外还有另一个浓度范围,即所谓的剂量相关参考浓度范围。治疗参考浓度范围的应用是药效动力学问题,而剂量相关参考浓度范围的运用是药代动力学问题。后者比较的是测得的药物浓度与理论预期药物浓度范围。参照药代动力学研究,优先考虑没有合并用药或药物基因组异常的患者群(“正常”患者),在日维持剂量(Daily maintenance dose,D m)、给药间隔(Dosing interval,d i)、总清除率(Total clearance,CL)和生物利用度(Bioavailability,F)已知情况下,某种药物在某个“正常”患者体内的预期平均稳态浓度(Average steady-state concentration,C av)可通过下面的公式计算。

关 键 词：治疗药物监测 药效动力学 给药间隔 维持剂量 生物利用度 药物浓度 药代动力学 合并用药 

分 类 号：R964[医药卫生—药理学]